Growth drivers Position QIAGEN's expanding product portfolio, including QIAstat-Dx and AMR panels, as a platform for rapid pathogen detection and antimicrobial resistance profiling to capture increased demand from healthcare providers and laboratories facing outbreaks and rising infectious disease scrutiny.

Strategic partnerships Leverage ongoing collaborations and integrations (Inpeco/Diasorin, NVIDIA AI) to penetrate multi-site diagnostics labs, hospital networks and research institutions seeking automated sample-to-insight workflows, enabling higher throughput and reduced time-to-result.

Public health relevance Highlight solutions that support outbreak response and public health surveillance (cyclosporiasis, bloodstream infections) to target government, regional health authorities and hospital systems investing in molecular testing capacity and surveillance programs.

Automation emphasis Capitalize on automation initiatives across sample prep, analysis and reporting to appeal to high-volume labs seeking cost efficiencies, reproducibility and scalable workflows in molecular diagnostics and life sciences research.

Financial and investor interest Monitor takeover interest and potential strategic accelerants from private equity participants and public markets to identify opportunities for upselling bundled solutions, service contracts and expanded platform adoption as part of a broader buy-side due diligence narrative.